Aptivus "Suboptimal" Comparator Arm Likely Key Issue For Antivirals Cmte.
This article was originally published in The Pink Sheet Daily
Executive Summary
The majority of comparator patients in the pivotal RESIST trials were resistant to their assigned agent, FDA says. The agency's reanalysis of the trials, however, continues to show statistical significance for tipranavir. Safety issues for Boehringer Ingelheim's HIV drug include hepatotoxicity and drug-drug interactions.
You may also be interested in...
Aptivus Needs Further Studies To Guide Use After Accelerated Approval, Cmte. Says
More information is needed on appropriate HIV patient populations and how to manage adverse events, FDA's Antiviral Drugs Advisory Committee says. Accelerated approval is recommended by 11-to-3 vote for use of Boehringer Ingelheim's tipranavir in heavily pre-treated patients.
Aptivus Needs Further Studies To Guide Use After Accelerated Approval, Cmte. Says
More information is needed on appropriate HIV patient populations and how to manage adverse events, FDA's Antiviral Drugs Advisory Committee says. Accelerated approval is recommended by 11-to-3 vote for use of Boehringer Ingelheim's tipranavir in heavily pre-treated patients.
Boehringer Ingelheim Aptivus To Get FDA Advisory Committee Review In May
Tipranavir will be considered by FDA's Antiviral Drugs Advisory Committee for the treatment of patients with multi-drug-resistant HIV. In clinical trials, use of the protease inhibitor was associated with GI adverse events and elevated triglycerides.